Abstract
Our knowledge and understanding of the underlying neurobiology and symptomatic expression of ADHD has advanced dramatically over the past decade. Associated with these advances has been a similar explosion of new treatment options to individualize treatment for our patients. This article will: ∙ review strategies to measure ADHD symptoms and functional difficulties while seeking to achieve full symptomatic remission throughout the day ∙ summarize recent findings regarding the management and prioritization of ADHD and comorbid conditions and ∙ discuss the various pharmacologic treatment options with a focus on recently developed molecules and novel delivery systems.
Keywords:
ADHD; attention deficit/hyperactivity disorder; pharmacology; rating scales; review.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adrenergic Uptake Inhibitors / therapeutic use*
-
Adrenergic alpha-2 Receptor Agonists / therapeutic use*
-
Anxiety Disorders / epidemiology
-
Anxiety Disorders / therapy
-
Atomoxetine Hydrochloride / therapeutic use
-
Attention Deficit Disorder with Hyperactivity / drug therapy*
-
Attention Deficit Disorder with Hyperactivity / epidemiology
-
Bipolar Disorder / epidemiology
-
Bipolar Disorder / therapy
-
Central Nervous System Stimulants / administration & dosage*
-
Clonidine / therapeutic use
-
Comorbidity
-
Delayed-Action Preparations
-
Depressive Disorder / epidemiology
-
Depressive Disorder / therapy
-
Dextroamphetamine / administration & dosage
-
Guanfacine / therapeutic use
-
Humans
-
Methylphenidate / administration & dosage
Substances
-
Adrenergic Uptake Inhibitors
-
Adrenergic alpha-2 Receptor Agonists
-
Central Nervous System Stimulants
-
Delayed-Action Preparations
-
Methylphenidate
-
Guanfacine
-
Atomoxetine Hydrochloride
-
Clonidine
-
Dextroamphetamine